All News

2060 articles, sorted by publication time.

Cancer Treatment · global

Six-Year Follow-Up in Adjuvant Breast Cancer Treatment: Higher Survival in the Kisqali Group, but Statistical Interpretation Still Requires Caution

The phase III NATALEE trial shows a 2.2-percentage-point increase in six-year overall survival with the addition of ribociclib. This provides new long-term evidence for postoperative treatment, but the descriptive analysis and smaller subgroup samples also define the limits of what the results can answer.

Cancer Research · us

Getting Cancer Cells to Break Down the Androgen Receptor: Prostate Cancer Drug Trial Reveals Differences Between Mutation Subgroups

The oral drug bavdegalutamide showed antitumor activity in an early trial, with more pronounced responses in a small subgroup of patients with specific receptor mutations. But the marked differences between subgroups also show that protein degradation therapies need more precise identification of suitable patients.